Zobrazeno 1 - 10
of 80
pro vyhledávání: '"GR Sareddy"'
Autor:
RK Vadlamudi, GR Sareddy, Ganesh V. Raj, Mei Kuen Li, Rajeshwar Rao Tekmal, S Ma, J-M Ahn, Mei Zhou, T-K Lee, EM Blatt, Xihui Liu, Suryavathi Viswanadhapalli, Dede N. Ekoue
Publikováno v:
Cancer Research. 79:P4-07
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and represents a disproportional share of the breast cancer mortality, primarily due to a lack of targeted therapies. There is a major unmet need for rationall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::395a3d99a270187bbc362b69c972629e
https://doi.org/10.1158/1538-7445.sabcs18-p4-07-01
https://doi.org/10.1158/1538-7445.sabcs18-p4-07-01
Autor:
Manjeet K. Rao, Annabel Chang, Marek Bajda, Kristin A. Altwegg, Ramachandran Murali, Kalarickal V. Dileep, Mei Zhou, Vijaya Manthati, GR Sareddy, Xinlei Pan, Yiliao Luo, Kam Y. J. Zhang, Hareesh B. Nair, Uday P. Pratap, Xiaonan Li, Ganesh V. Raj, Mengxing Li, Andrew Brenner, U Srinivasan, RK Vadlamudi, Rajeshwar Rao Tekmal, Bindu Santhamma, Klaus J. Nickisch, S Ma, AC Riveros, Suryavathi Viswanadhapalli
Publikováno v:
Cancer Research. 79:P2-06
Background: Leukemia inhibitory factor (LIF) and its receptor LIFR are over-expressed in multiple solid tumors and play a key role in tumor growth, progression, and resistance to standard anti-cancer treatments. Triple-negative breast cancer (TNBC) l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13e933b56cff9779cec67a6f27a132e2
https://doi.org/10.1158/1538-7445.sabcs18-p2-06-02
https://doi.org/10.1158/1538-7445.sabcs18-p2-06-02
Autor:
Rajeshwar Rao Tekmal, Mei Zhou, T-K Lee, Suryavathi Viswanadhapalli, Xiaonan Li, Ganesh V. Raj, GR Sareddy, RK Vadlamudi, E Ali, J-M Ahn, S Ma
Publikováno v:
Cancer Research. 78:P1-09
BACKGROUND: Recently,CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) is approved for the treatment of ER+ advanced breastcancer (BCa). However, not all patients benefit from CDK4/6 inhibitors therapy. Emerging studies indicate m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::725831cb5310d315fa7dca8a82d845f1
https://doi.org/10.1158/1538-7445.sabcs17-p1-09-06
https://doi.org/10.1158/1538-7445.sabcs17-p1-09-06
Autor:
GR Sareddy, Suryavathi Viswanadhapalli, Hui Yan, Maria E. Fernandez, Carlos E. Rivera, RK Vadlamudi, Paolo Casali
Publikováno v:
Cancer Research. 79:P4-06
How host immune elements, particularly B cells, are hijacked to promote breast cancer (BCa) tumor progression and acquisition of resistance to current endocrine therapies remain largely unclear. Prompted by our recent findings that B cells are a majo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8ae1f097ecc649526fdbd0aebfce160
https://doi.org/10.1158/1538-7445.sabcs18-p4-06-15
https://doi.org/10.1158/1538-7445.sabcs18-p4-06-15
Autor:
Rajeshwar Rao Tekmal, Weiwei Tang, Xiaonan Li, GR Sareddy, Kristin A. Altwegg, Suryavathi Viswanadhapalli, Kumaraguruparan Ramasamy, Zexuan Liu, Ratna K. Vadlamudi, Junhao Liu, Sureshkumar Mulampurath Achuthan Pillai, Logan Blankenship, Swapna Konda, Behnam Ebrahimi, Prabhakar P. Vekata, Bindu Santhamma, Uday P. Pratap, Hareesh B. Nair, Edward R. Kost
Publikováno v:
Cancer Research. 81:1253-1253
Background: Endometrial cancer (EC) is the fourth most common cancer in women. Approximately 80% of EC belong to the endometroid-EC subtype and are driven by estrogen signaling. Advanced-stage EC has limited treatment options with poor prognosis. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee40799d98674db20c7381c829e9c824
https://doi.org/10.1158/1538-7445.am2021-1253
https://doi.org/10.1158/1538-7445.am2021-1253
Autor:
Gabrielle Gray, Yihong Chen, Siyuan Zheng, GR Sareddy, Bridgitte E. Palacios, Yi He, Rajeshwar Rao Tekmal, Andrew Brenner, Uday P. Pratap, Suryavathi Viswanadhapalli, Salvador Alejo, Prabhakar Pitta Venkata
Publikováno v:
Cancer Research. 81:2026-2026
Background: Glioblastoma (GBM) is the most common malignant brain tumor with a dismal prognosis and median survival of 20 months. Standard therapy consists of surgical resection, external beam radiation therapy, adjuvant chemotherapy with temozolomid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::455a98521352d187abaa77eee73d43b1
https://doi.org/10.1158/1538-7445.am2021-2026
https://doi.org/10.1158/1538-7445.am2021-2026
Autor:
Mengxing Li, Shihong Ma, Weiwei Tang, GR Sareddy, Junhao Liu, Ganesh Raj, Ratna K. Vadlamudi, Xihui Liu, Tae-Kyung Lee, Xiaonan Li, Jung-Mo Ahn, Rajeshwar Rao Tekmal, Suryavathi Viswanadhapalli
Publikováno v:
Cancer Research. 81:1237-1237
Background: Women with triple-negative breast cancer (TNBC) have a more aggressive clinical course, with a higher propensity to metastasize and a worse outcome due to a lack of effective therapies and significant intratumoral and intertumoral heterog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6581f3fc3bbf2d97b39f3e33192b0c03
https://doi.org/10.1158/1538-7445.am2021-1237
https://doi.org/10.1158/1538-7445.am2021-1237
Autor:
GR Sareddy, Darrell W. Brann, Monica Mann, L Xaionan, Suryavathi Viswanadhapalli, Hariprasad Vankayalapati, RK Vadlamudi
Publikováno v:
Cancer Research. 76:P1-06
BACKGROUND: Evolving evidence suggests that cancer stem cells (CSCs) evade hormonal therapy and therapy resistance occurs due to regrowth of tumor cells from cancer stem cells that escaped hormonal therapy or remained in the body after tumor resectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7628de18e4cd78433afa255b586552f3
https://doi.org/10.1158/1538-7445.sabcs15-p1-06-09
https://doi.org/10.1158/1538-7445.sabcs15-p1-06-09
Publikováno v:
Cancer Research. 79:P2-02
INTRODUCTION: Fatty acid synthase (FASN) is a key enzyme in tumor cell biology controlling endogenous lipid biosynthesis. It is overexpressed in a biologically aggressive subset of tumors, including breast carcinoma. We previously reported prolonged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f00e8fecad2959da95232c96cc0cd73
https://doi.org/10.1158/1538-7445.sabcs18-p2-02-03
https://doi.org/10.1158/1538-7445.sabcs18-p2-02-03
Autor:
GR Sareddy, Yiliao Luo, Suryavathi Viswanadhapalli, SE Weintraub, J-M Ahn, S Ma, Carlos L. Arteaga, RK Vadlamudi, Xihui Liu, Prasanna G. Alluri, T-K Lee, Kara Kassees, Dede N. Ekoue, Ganesh V. Raj, A Alluri, Rajeshwar Rao Tekmal
Publikováno v:
Cancer Research. 79:P5-04
Background:We had previously reported a novel small molecule, ERX-11, that directly interacts with ER and blocks the interaction between a subset of coregulators with both native and mutant forms of ER. ERX-11 effectively blocks ER oncogenic signalin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::028cb7308af60b34524e667177d1a9a4
https://doi.org/10.1158/1538-7445.sabcs18-p5-04-23
https://doi.org/10.1158/1538-7445.sabcs18-p5-04-23